Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Has a primary diagnosis of schizophrenia established by a comprehensive psychiatric evaluation based on the DSM-5 (American Psychiatric Association 2013) criteria and confirmed by Mini International Neuropsychiatric Interview (MINI) for Schizophrenia and Psychotic Disorder Studies version 7.0.2.
Positive and Negative Syndrome Scale (PANSS) total score of ≤ 80 at screening and Baseline.
Clinical Global Impression-Severity (CGI-S) score of ≤ 4 at screening and Baseline.
Willing and able to discontinue all antipsychotic medications prior to baseline visit.
You may not be if
History or presence of clinically significant cardiovascular, pulmonary, renal, hematologic, gastrointestinal (GI), endocrine, immunologic, dermatologic, neurologic, or oncologic disease or any other condition that, in the opinion of the investigator, would jeopardize the safety of the participant or the validity of the study results.
Any primary DSM-5 disorder other than schizophrenia within 12 months before screening.
History of treatment resistance to schizophrenia medications.
History of allergy/hypersensitivity to KarXT.
Clareo Health | Study to Assess Safety and Effectiveness of Slowly Increasing Dose and Food Effect of KarXT in Participants With Schizophrenia
